EGFR and non-small cell lung carcinoma: Thus, due to their increased benefit on progression-free survival (PFS) and mild adverse effects, certain FDA- (US Food and Drug Administration) and EMA- (European Medicines Agency) approved EGFR TKIs such as erlotinib and gefitinib are usually implemented as first-line therapy for patients with advanced NSCLC [14,17,18,19].